Triethylene Thiophosphoramide in the Treatment of Previously Hypophysectomised Patients with Carcinoma of the Breast
1959

Triethylene Thiophosphoramide for Breast Cancer Treatment

Sample size: 18 publication Evidence: moderate

Author Information

Author(s): K. J. Gurling

Primary Institution: Royal Free Hospital and School of Medicine, London

Hypothesis

Can triethylene thiophosphoramide improve outcomes in patients with breast cancer who have undergone hypophysectomy?

Conclusion

Triethylene thiophosphoramide led to objective improvement in 56% of patients with advanced breast cancer who had previously undergone hypophysectomy.

Supporting Evidence

  • 56% of patients showed objective improvement after treatment with thiotepa.
  • Seven patients maintained improvement for eight weeks or more.
  • Four patients experienced significant relief from bone pain due to metastases.

Takeaway

This study tested a drug called thiotepa on women with breast cancer who had surgery that usually doesn't help them anymore, and it worked for some of them.

Methodology

Patients received intramuscular injections of thiotepa, starting with 5 mg daily for five days, with adjustments based on blood cell counts.

Limitations

The study had a small sample size and the improvements were often temporary.

Participant Demographics

Eighteen women who had previously undergone surgical hypophysectomy.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication